Sanofi participates in the production of 100 million doses of Pfizer / BioNTech vaccine

by



[ad_1]

The French company will aim to help deliver more than 100 million doses of the vaccine this year from its German factory in Frankfurt, CEO Paul Hudson told Le Figaro newspaper on Tuesday.

Pfizer and its German partner BioNTech, like other Covid-19 vaccine makers such as AstraZeneca, are struggling to meet the huge demand for vaccines which are the world’s best bet for overcoming the pandemic.

Last month, Sanofi and Britain’s GlaxoSmithKline said a Covid-19 vaccine they were jointly developing had shown an insufficient immune response in the elderly, delaying its launch until the end of this year.

The company has since been under pressure to look for ways to help with Covid-19 vaccines designed by other drugmakers as the pandemic escalates again in Europe and elsewhere.

“Since our main vaccine is a few months behind schedule, we wondered how we could be of help now,” said Hudson.

Sanofi is also working on another Covid-19 vaccine candidate with the American company Translate Bio which uses mRNA technology, similar to Pfizer / BioNTech’s approach. Phase I trials are scheduled to begin this quarter.

Hudson confirmed in the interview that Sanofi remains committed to its two vaccine projects.

[ad_2]

Source link